12:00 AM
 | 
Jan 14, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Juxtapid lomitapide: Phase I started

Last quarter, Aegerion began a double-blind, placebo-controlled Phase I trial to evaluate single and multiple ascending-doses of Juxtapid in about 72 Japanese and Caucasian male volunteers. The company said it plans to follow the...

Read the full 149 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >